<![CDATA[Savolitinib Combo Improves PFS, OS in EGFR-Mutated NSCLC Trial]]>

Data ReadoutpositiveSavolitinibPositive

AI Analysis

Summary

SAFFRON trial data shows savolitinib combination therapy improved progression-free and overall survival in EGFR-mutated NSCLC patients with MET-driven resistance, potentially advancing treatment options in this patient population.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Improved progression-free survival and overall survival in combination therapy

Importance:7/10

Sentiment:

0.80

NSCLCEGFR-mutatedMET-driven resistanceSAFFRON trialcombination therapyPFSOS

Read the original article

Published by Cancer Network on August 17, 2026 2:30 PM

Read Original